• Molecular NameDipivefrine
  • SynonymNA
  • Weight351.443
  • Drugbank_IDDB00449
  • ACS_NO52365-63-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.22
  • pkaN/A
  • LogD (pH=7, predicted)0.12
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.74
  • LogSw (predicted, AB/LogsW2.0)2.48
  • Sw (mg/ml) (predicted, ACD/Labs)0.61
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds9
  • TPSA84.86
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution . It causes vasoconstriction, decreased aqueous humor production, and decreases intraoccular pressure. It gets converted to epinephrine upon penetrating the cornea.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmDipivefrin is converted to epinephrine inside the human eye by enzyme hydrolysis through formation of 3- and 4-monopivaloylepinephrine..
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)183 mg/kg.
  • LD50 (mouse)N/A